Cargando…

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iacoboni, Gloria, Villacampa, Guillermo, Martinez‐Cibrian, Nuria, Bailén, Rebeca, Lopez Corral, Lucia, Sanchez, Jose M., Guerreiro, Manuel, Caballero, Ana Carolina, Mussetti, Alberto, Sancho, Juan‐Manuel, Hernani, Rafael, Abrisqueta, Pau, Solano, Carlos, Sureda, Anna, Briones, Javier, Martin Garcia‐Sancho, Alejandro, Kwon, Mi, Reguera‐Ortega, Juan Luis, Barba, Pere
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124109/ https://www.ncbi.nlm.nih.gov/pubmed/33932100 http://dx.doi.org/10.1002/cam4.3881

Ejemplares similares

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022)

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2022)

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel
por: Martín‐Rojas, Reyes Maria, et al.
Publicado: (2022)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022)

Tisagenlecleucel for B-cell cancers
Publicado: (2019)

Tisagenlecleucel: Hypogammaglobulinaemia and pancytopenia: case report
Publicado: (2021)

Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2022)

P1151: BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
por: Garcia-Calvo, Gloria Ines Iacoboni, et al.
Publicado: (2023)

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
por: Hall, Erin M, et al.
Publicado: (2021)

Tisagenlecleucel: Prolonged neutropenia and thrombocytopenia: case report
Publicado: (2022)

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Publicado: (2021)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
por: Salles, Gilles, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
por: Ribera Santasusana, Josep Maria, et al.
Publicado: (2020)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Vaccination Against Sars-Cov-2 Induces Robust Humoral Immune Response in Patients with Previous Hematologic Stem Cell Transplantation
por: Roldan, Elisa, et al.
Publicado: (2022)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
por: Abrisqueta, Pau, et al.
Publicado: (2022)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, David, et al.
Publicado: (2018)

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
por: Goto, Hideki, et al.
Publicado: (2020)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
por: Jaeger, Ulrich, et al.
Publicado: (2022)

PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma
por: Ligero, Marta, et al.
Publicado: (2023)

Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study
por: Solano, Carlos, et al.
Publicado: (2023)

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018)

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
por: Stein, Andrew M., et al.
Publicado: (2019)

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma
por: Yamasaki-Morita, Makiko, et al.
Publicado: (2022)

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
por: Awasthi, Rakesh, et al.
Publicado: (2023)

Is Post-Transplant Cyclophosphamide the New Methotrexate?
por: Mussetti, Alberto, et al.
Publicado: (2021)

Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era
por: Mussetti, Alberto, et al.
Publicado: (2022)

Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
por: Zavras, PD, et al.
Publicado: (2019)

Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation
por: Ipe, Abraham, et al.
Publicado: (2023)

CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
por: Velasco, Roser, et al.
Publicado: (2023)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

Defining the Nature of Thermal Intermediate in 3 State Folding Proteins: Apoflavodoxin, a Study Case
por: García-Fandiño, Rebeca, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4dboq2j43pm301ohlbaobl2ic0